A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes.
Dipeptidyl peptidase-4 inhibitor
HbA1c
Seasonal effect
Sitagliptin
Type 2 diabetes
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
29
01
2020
accepted:
21
02
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
ppublish
Résumé
There are several reports of seasonal variation in hemoglobin A1c (HbA1c) in patients with type 2 diabetes (T2DM), but no reports of seasonal variation in the effect of add-on drugs on blood glucose control in insulin-treated patients. Using data collected from 630 patients in a multicenter study, we compared the amount of change in HbA1c after 1, 3, 6, 9, and 12 months of add-on administration of sitagliptin in insulin-treated patients divided into four groups based on the month when sitagliptin was started. A significantly larger decrease in HbA1c at 6 months from baseline was observed in the group that started add-on sitagliptin in February to April than in the other three groups. However, the amount of change in HbA1c at 12 months did not differ among the groups. The consideration of seasonal variation enables more accurate evaluation of a drug's short-term effect on blood glucose control.
Sections du résumé
BACKGROUND
BACKGROUND
There are several reports of seasonal variation in hemoglobin A1c (HbA1c) in patients with type 2 diabetes (T2DM), but no reports of seasonal variation in the effect of add-on drugs on blood glucose control in insulin-treated patients.
METHODS
METHODS
Using data collected from 630 patients in a multicenter study, we compared the amount of change in HbA1c after 1, 3, 6, 9, and 12 months of add-on administration of sitagliptin in insulin-treated patients divided into four groups based on the month when sitagliptin was started.
RESULTS
RESULTS
A significantly larger decrease in HbA1c at 6 months from baseline was observed in the group that started add-on sitagliptin in February to April than in the other three groups. However, the amount of change in HbA1c at 12 months did not differ among the groups.
CONCLUSIONS
CONCLUSIONS
The consideration of seasonal variation enables more accurate evaluation of a drug's short-term effect on blood glucose control.
Identifiants
pubmed: 32231757
doi: 10.14740/jocmr4103
pmc: PMC7092762
doi:
Types de publication
Journal Article
Langues
eng
Pagination
200-208Informations de copyright
Copyright 2020, Takai et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Clin Med Res. 2016 Jun;8(6):461-71
pubmed: 27222674
Intern Med. 2019 Apr 15;58(8):1067-1072
pubmed: 30626812
Diabetes Care. 2001 Aug;24(8):1503
pubmed: 11473100
J Korean Med Sci. 2014 Apr;29(4):550-5
pubmed: 24753703
J Clin Med Res. 2015 Aug;7(8):607-12
pubmed: 26124906
J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46
pubmed: 11889194
Diabetes Res Clin Pract. 2014 Mar;103(3):e30-3
pubmed: 24525293
Diabetes Obes Metab. 2010 Jul;12(7):613-22
pubmed: 20590736
Diabetes Res Clin Pract. 2010 Apr;88(1):65-70
pubmed: 20047769
Diabetes Care. 2004 May;27(5):1238-9
pubmed: 15111560
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
Nutr Metab Cardiovasc Dis. 2010 May;20(4):224-35
pubmed: 19515542
Diabetes Res Clin Pract. 2012 Jan;95(1):e20-2
pubmed: 22055835
Pediatrics. 1979 Mar;63(3):374-9
pubmed: 440839
Diabetes Res Clin Pract. 2012 Jun;96(3):e53-4
pubmed: 22153414
J Diabetes Investig. 2018 Sep;9(5):1159-1166
pubmed: 29427314
Diabetes Care. 2014;37(5):e98-9
pubmed: 24757253
J Clin Med Res. 2019 May;11(5):311-320
pubmed: 31019624
Intern Med. 2013;52(24):2721-6
pubmed: 24334574
J Clin Med Res. 2013 Jun;5(3):217-21
pubmed: 23671547
Arch Endocrinol Metab. 2015 Jun;59(3):231-5
pubmed: 26154091
Prim Care Diabetes. 2009 May;3(2):111-4
pubmed: 19535310